J. E. Roulston

Learn More
We examined the prognostic value of early serum CA125 assay in 58 patients with advanced epithelial ovarian cancer together with residual disease, age, tumour grade, performance status, and the presence of ascites or adhesions at primary surgery. CA125 was a highly significant predictor of both progression free and overall survival after the first cycle and(More)
We assayed serum HMFG2 in serial samples from 215 primary epithelial ovarian cancer patients using an 'in-house' single determinant ELISA, 45% of patients with stage I, 54% with stage II, 61% with stage III and 75% with stage IV disease had elevated serum HMFG2. Post-operative levels were significantly related with residual tumour volume (P < 0.005), and(More)
is but one example which highlights the search for serological tumour markers to facilitate earlier diagnosis of usually intractable disease. The rationale lies in the hope that earlier diagnosis will increase curability. Before looking at the claims of CA 242 and pancreatic cancer in particular, it is worth perhaps reconsidering what are the possible roles(More)
It is an appropriate time to bring together the various groups working in the UK on markers of breast and ovarian cancer. Physicians are interested in the problems of how to use markers for screening, management of advanced disease and increasing imaging and therapy targeting. These main areas of interest formed the basis of the sessions allocated for paper(More)
  • 1